Corcept Therapeutics, Inc. (NASDAQ:CORT)
| CAPS Rating |
|
|---|---|
| Open | $3.05 |
| Previous Close | $3.08 |
| Daily Range | $2.50 - $3.05 |
| 52-Week Range | $2.51 - $5.07 |
| Market Cap | $232.40M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,535,675 |
| Average Daily Volume | 0 |
CORT
VS S&P 500 (SPY)
How do you think CORT will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CORT Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CORT News and Commentary
- Amgen, Vivus, Chelsea Therapeutics Prep for Key Catalysts in February – Minyanville
- Regeneron Wins FDA Approval for Eye Drug: 3 Companies Up For Approval – NASDAQ
- Insider Picks: 5 Biotech Stocks Being Snapped Up By Insider Executives – SeekingAlpha
- 7 Upcoming Biotech Catalysts – SeekingAlpha
- 5 Stocks Under $5 With Conservative Accounting Practices – SeekingAlpha
- 22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12 – SeekingAlpha
- You're Not the Only One Buying Here – The Motley Fool
- 9 Stocks Under $5 Dragged Down by Institutional Selling – SeekingAlpha
- 20 Short Seller Targets Under $5 – SeekingAlpha
- Neoprobe Looks to Become a Major Player in Oncology – SeekingAlpha
- Corcept Still Down but Positive Phase III Results Herald Potential Gains in 2011 – SeekingAlpha
- Corcept May Have Hit Pay Dirt – The Motley Fool
- Interview: Corcept Therapeutics CFO on Corlux Phase 3 Results – SeekingAlpha
- Four Biotechs Positioned for Strong 2010 Finish – SeekingAlpha
- December Will Be Exciting for Up and Coming Corcept Pharmaceuticals – SeekingAlpha
- The 20 Most Undervalued Biotech Stocks – SeekingAlpha
- Analyst Calls: CAH, EXPE, FSLR, HOT, LVS, MWW, NUVA, POT ... – BloggingStocks
- Two new put candidates – Blog at The Motley Fool
- Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? – The Motley Fool
- Ugly Side Effects Won't Derail This Drug – The Motley Fool
RSS Headlines
Fool UK
